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Abstract  
Introduction: Britain’s cancer survival results have 
been criticised as being significantly higher than twenty 
Major Developed Countries (MDC). Hence this 
comparison of current UK Total Age-Standardised-
Death-Rates (ASDR), female Breast and Prostate cancer 
mortality rates with twenty (MDC) between1989 to 
2015 to determine any significant change. 
 
Method: WHO data ASDR per million (pm)  for Total, 
Breast and Prostate cancer mortality rates examined for 
the years 1989-91 to 2013-15.  Confidence Intervals (+/- 
95%) are used to determine any significant differences 
between the UK and other country’s outcomes over the 
period. Chi square tests for each nation’s Breast and 
Prostate mortality. 
 
Results:  Every country’s Total ASDR, Breast and 
Prostate cancer mortality fell except Greece and Japan. 
Total ASDR Male cancer mortality rates ranged from 
Portugal 1653pm to Sweden 1232pm. UK at 1475pm 
were 10th but had been 6th highest. Total ASDR Female 
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rates went from Denmark’s 1176pm to Japan’s 740pm, 
the UK 1092pm now 5th but previously had been second 
highest. No country’s Total rates fell significantly more 
than Britain’s who had significantly bigger reductions 
than four other countries for both sexes. Breast 
mortality ranged from Ireland’s 206pm to Japan’s 
99pm, UK rates fell significantly more than five 
countries. Whilst Breast mortality fell in every country 
Norway and UK had significantly bigger reductions in 
Breast than Prostate deaths, conversely France’s 
Prostate rates fell more than Breast mortality. Prostate 
mortality went from Norway 213pm Japan’s 60pm, the 
UK 167pm and five countries had greater reductions 
than Britain. 
 
Conclusions: Results reflect well on UK services for 
Total and Breast cancers, showing the NHS achieving 
more with proportionately less as Britain spends less on 
health than most MDC. The need how to improve UK 
prostate results are briefly discussed, such as a public 
information campaign to match the successful Breast 
cancer aware programme of the 1990’s.  
 
Keywords: Prostate Cancer; Breast Cancer; 
International Comparison 
 
1. Introduction  
UK cancer survival rates have been found to be poorer 
than some other developed countries [1-3]. However, 
survival rates as a measure of improved treatment have 
been criticised as being less accurate [4, 5] and that 
measuring mortality rates provides a better indication of 
relative effectiveness [6]. Moreover, over the past two 
decades there have been major reductions in cancer 
mortality in most of twenty-one Major Developed 
Countries (MDC) [6-8]. These improvements are 
associated with reduced smoking, a confirmatory 
indicator that life-style behaviour is linked to the 
development of cancer [9, 10].  This is exemplified by 
the association of raised BMI with neoplastic disease 
[11], and the multiplicity of contributory causes for 
cancer, the role of both genetic and epigenetic factors 
being readily acknowledged [12-14]. However, findings 
both in the USA and the UK point towards the 
importance of strong socio-economic factors. Thus, 
variations in cancer mortality between people in higher 
and lower socio-economic groups and in the richer and 
poorer regions of Britain, highlight the significance of 
wider environmental factors in addition to any 
underlying genetic predisposition [15-18]. 
 
One intriguing finding is that Western Europe - which 
contains 9% of the world population - has 25% of the 
world incidence of cancer [8]. Is this because of the 
greater availability of diagnostic services?. For example, 
with prostate cancer rates have never been so high but 
this is ascribed to the use of PSA testing and improved 
diagnosis. Moreover, some have stated that the use of 
screening may have resulted in an over diagnosis of 
prostate cancer, with the detected cancer often being of 
low malignant potential and with no need for invasive 
treatment [19-21]. In a study of the current incidence of 
cancer in Europe there were 3.91 million new cases in 
2018, the most prevalent sites being breast, colorectal, 
lung and prostate [8]. A recent study on the projections 
of cancer in Europe from 2015 up to 2035 suggested 
that there will be a slight decrease in male cancer rates 
(0.03%) but an increase of 0.11% in female cancer rates 
[7]. This raises the question of why? Thus, although any 
long- term study of cancer mortality rates will show that 
female cancer mortality is generally still lower than 
males - the gap has narrowed. It also suggests that 
macro socio-economic changes, perhaps related in- part 
to the greater integration of women into the work place, 
has led to a situation where they too are now at a similar 
risk of exposure to any work related environmental 
carcinogenic triggers, as their male counterparts [11, 13, 
14].  
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These questions have led to this explorative study that 
examines changes in Total cancer rates, as reported 
using WHO Age-Standardised-Death-Rates (ASDR), 
which control for age, gender and population and of the 
archetypal gender cancers of female breast and prostate 
disease in the UK compared with the twenty other MDC 
[22]. We have placed the analysis within an 
international comparative perspective because earlier 
research on post-diagnosis cancer survival was quite 
critical of the UK survival results [1-3].  However, there 
are inherent problems in measuring survival rates, 
which were often based upon different baselines [4, 5], 
whereas it has been shown that counting actual 
mortality rates resolves this dilemma and provides a 
firmer comparative parameter [6]. Consequently, we ask 
whether over the past twenty-five years, have there been 
any significant differences in the reductions between 
total ASDR for ALL cancers by gender with a separate 
analysis of female breast and prostate mortality rates in 
the UK compared to the other twenty MDC. The 
working null hypothesis is that there will be no 
statistically significant difference in the reductions 
between male and female total cancer mortality and 
between female breast and prostate cancer deaths, 
between the UK and other MDC over the period 1989-
91 and 2013-15. 
 
2. Methods 
This is a population-based study. All mortality data is 
drawn from the latest WHO annual statistics, updated 
May 2018 [22]. The output of national efforts to 
effectively prevent and treat cancer, can be seen in the 
current WHO Total cancer mortality statistics based 
upon Age-Standardised-Death-Rates (ASDR) per 
million (pm) for ALL Malignant Neoplasm deaths by 
sex  in the International Classification of Diseases 
(coded C00 – C97) [23]. This is used in WHO data and 
for ASDR for Prostate cancer deaths (ICD 10 coded 
C61) and female Breast cancer (ICD 10 coded C50) 
rates per million (pm) [23]. Age-Standardised-Death-
Rates (ASDR) are used to compare between different 
countries, crucially based upon estimates of the average 
world population age-structure constructed for the 
period 2000-2025. The use of an average world 
population as well as a time series of observations, 
removes the effects of historical events such as wars and 
famine on population age composition [22]. It should be 
noted that the WHO Age-Standardized-Death-Rates 
based on the new standard are not comparable to 
previous estimates that are based on some earlier 
standard [22]. However, WHO acknowledge that to 
some extent for European countries, there is a slight 
inherent emphasis on how elderly rates contribute to the 
final ASDR. The real value of using ASDR is that it 
creates an equality between rates in different countries 
highlighting the true variation between countries after 
controlling for age, sex, population and disease patterns. 
Thus, the use of ASDR is a more powerful comparative 
rate enables comparisons to be made between countries 
of differing size, age structure from which to produce a 
percentage or ratio of change in mortality rates over the 
period.  
 
The baseline years are the 3years averages for 1989-91, 
compared with the index 3year average for 2013-15. 
Four countries have earlier index years, Canada and 
New Zealand 2011-13 and France and Ireland for 2012-
14. Any significant differences between the UK and the 
other MDC are tested by calculating Confidence 
Intervals (+/- 95%) using the SPSS programme. In 
addition, any variation between a country’s female 
Breast and Prostate outcomes are compared by using chi 
square tests, with probability levels of <0.05 (2-tailed) 
which were considered statistically significant using 
data from the breast and prostate mortality tables. The 
study provides a profile of how well each nation has 
improved it cancer mortality, in particular for Breast 
and Prostate cancers, which was a major aim of the 
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`Strategy for Cancer’ of the UK government [24] and 
compares the UK outcomes between 1989-91 v 2013-15 
with the twenty other MDC.   
 
3. Results 
3.1 Total (ASDR) cancer mortality by sex  
3.1.1 Total male neoplasm ASDR: These are shown in 
Table 1 and demonstrates that every country reduced its 
Total mortality rates over the period 1989-91 to 2013-
15. The highest rates were seen in Portugal at 1653pm, 
followed by France at 1613pm and Greece at 1607pm 
down to lows in Sweden at 1232pm, Finland at 1241pm 
and Switzerland at 1255pm The UK was 10th highest at 
1475pm with the current average of the other MDC 
(minus the UK) being 1439pm. The UK improved its 
mortality relative position from previously being sixth 
highest to falling to tenth, even as all the other countries 
reduced their mortality rates.  
 
The average MDC reduction in Total male mortality 
rates was 27% to the UK’s 31%. Confidence Interval 
results showed that UK males had significantly bigger 
reductions in mortality than Portugal, Greece, Spain and 
Sweden, whilst no country had significantly bigger falls 
in total male cancer mortality rates than the UK over the 
period 
 
3.1.2 Female total neoplasm ASDR: The highest 
female Total ASDR was seen in Denmark at 1176pm 
followed by Ireland at 1152pm and the Netherlands at 
1143pm down to Japan at 740pm, Spain at 775pm and 
Portugal at 814pm, the other MDC averaged 946pm. 
The UK is now 5th at 1092pm after been third highest 
in the 1989-91 period. The other MDC average 
reduction was 16% to the UK’s 25%. Confidence 
Intervals showed that the UK had statistically 
significant larger reductions over the period than 
Australia, France, Greece, Italy and the Netherlands, 
whilst again no other country had bigger falls in total  
female cancer mortality than the UK. 
 
3.1.3 Female breast cancer ASDR:  Every country, 
except Japan had substantial reductions over the period, 
with falls ranging from -27% to -45%, with the other 
MDC averaging -35%. The highest current rates are in 
Ireland at 206pm, the Netherlands at 190pm and 
Germany and New Zealand at 177pm, down to lows of 
99pm in Japan, 118pm in Norway, and123pm in Spain, 
the other MDC averaged 156pm. The UK were fifth at 
174pm but previously had been second highest. The 
other MDC average reduction was 34% to the UK’s 
47% over the period. Confidence Interval results 
showed that the UK had significantly bigger reductions 
over the period than France, Germany, Greece, Japan 
and Portugal. Furthermore, no other nation had 
significantly greater falls in breast cancer mortality than 
the UK.  
 
3.1.4 Prostate cancer ASDR: Every country, except 
Greece (+6%) and Japan (+20%) had substantial falls in 
prostate mortality, ranging from -17% to -49%, the 
other MDC averaging 32% to the UK’s 22% fall over 
the period. Highest prostate cancer mortality rates were 
seen in Norway at 213pm, Sweden at 210pm and 
Denmark at 207pm. The lowest was 60pm in Japan, 
93pm in Italy and 108pm in the USA, the other MDC 
averaged 143pm. The UK’s position relatively 
worsened as Britain is now fifth highest at 167pm 
having previously been 15th of the twenty-one countries. 
Confidence Intervals showed that Austria, Belgium, 
Canada, France, and the USA had statistically 
significant bigger reductions in prostate cancer mortality 
than the UK over the period.  
 
3.1.5 Changes in national breast and prostate 
mortalities: In comparing each country’s breast and 
prostate outcomes over the period only France had a 
greater reduction in prostate deaths compared with falls 
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in breast cancer mortality (p<0.02). Conversely, there 
were significantly greater reductions in breast cancer 
compared to prostate cancer mortality in Norway 
(<0.04) and the UK (p<0.01). Thus, with these three 
exceptions the archetypal of male and female cancers 
had relatively similar improvements over the period in 
the majority of MDC.  
  
Country, Year, & Current rank   Males 1989-91 Males 2013-15   % of change    CI Lower      CI Upper 
1.Portugal  1704 1653 -3 1.27 1.54 
2.France 2012-14 2371 1613 -32 0.89 1.07 
3.Greece  1652 1607 -3 1.27 1.54 
4.Netherlands 2284 1577 -31 0.91 1.09 
5.Spain 2006 1544 -23 1.01 1.22 
6.Denmark 2186 1541 -30 0.92 1.11 
7.Belgium 2339 1510 -35 0.85 1.02 
8.Ireland 2012-14 2052 1504 -27 0.96 1.16 
9.Italy 2227 1490 -33 0.88 1.06 
10.UK 2124 1475 -31 0.91 1.10 
11. Germany 1990 2103 1475 -30 0.92 1.11 
12. New Zealand 2011-13 1986 1422 -28 0.94 1.13 
13.Austria 2093 1418 -32 0.89 1.07 
14.Japan 1977 1375 -30 0.91 1.10 
15.Canada 2011-13 1986 1360 -32 0.90 1.09 
16.Australia 1883 1330 -29 0.92 1.12 
17.Norway 1741 1318 -24 0.99 1.20 
18.USA 1949 1310 -33 0.88 1.07 
19.Switzerland 1993-95 1773 1255 -29 0.92 1.12 
20. Finland 1837 1241 -32 0.88 1.07 
21.Sweden 1555 1232 -21 1.03 1.26 
MDC Average (-UK) 1985 1439 -27   
Correlating ranks of % reduction with %GDPEH Rho= +0.4573 p<0.025.  
UK: MDC Significantly different CI in BOLD 
 
Table 1: Male Total Neoplasms ASDR per million 1989-2015. Ranked by Highest rates. Confidence Intervals 
Compares UK Reductions to Other Major Developed Countries. 
 
Country, Year & Current rank Female 1989-91 Female 2013-15 % of Change CI Lower CI Upper 
1.Denmark 1634 1176 -28 0.86 1.06 
2.Ireland 2012-14 1410 1152 -28 0.97 1.21 
3. Netherlands 1278 1143 -21 1.06 1.33 
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4. N. Zealand 2011-13 1451 1095 -25 0.90 1.12 
5.UK 1448 1092 -25 0.89 1.12 
6.Canada 2011-13 1272 1040 -19 0.97 1.21 
7.Germany 1990 1272 978 -23 0.91 1.14 
8.USA 1279 976 -25 0.90 1.13 
9.Sweden  1148 962 -18 0.99 1.25 
10.Belgium 1199 957 -23 0.94 1.19 
11.Norway 1186 947 -22 0.94 1.19 
12.Austria 1273 938 -27 0.87 1.10 
13.Italy 1148 922 -20 1.13 1.41 
14. Australia 1157 904 -19 0.92 1.16 
15.France 1054 893 -23 1.00 1.27 
16. Finland 1091 842 -23 0.91 1.15 
17. Greece 883 841 -8 1.12 1.43 
18. Switzerland 1993 1052 823 -21 0.92 1.17 
19. Portugal 1011 814 -19 0.95 1.21 
20. Spain 962 775 -19 0.94 1.21 
21. Japan 913 740 -19 0.95 1.22 
Average (-UK) 1120 946 -16   
Correlating ranks of % reduction with %GDPEH Rho= +0.15999 n.sig.  
UK: MDC Significantly different CI in BOLD 
 
Table 2: Female Total Neoplasms ASDR per million 1989-2015 ranked by highest rates. Confidence Intervals 
Compares UK Reductions to Other Major Developed Countries. 
 
Country, Years &  Current rank Breast 1989 v 2015 % Change 
CI  UK:MDC 
Lower Upper 
1. Ireland  2012-14  336 – 206 -39 0.89 1.48 
2. Netherlands    303 – 190 -37 0.91 1.52 
3. Germany 1990  244 – 177 -27 1.04 1.78 
3. New Zealand 2011-13  298 – 177 -40 0.86 1.45 
5.UK         326 - 174  -47 0.77 1.30 
6. Denmark       288 – 172 -40 0.86 1.45 
7. France 2012-14    219 – 170 -28 1.11 1.91 
8. Italy    233 – 160 -31 0.98 1.69 
9. Austria      247 – 158 -36 0.91 1.57 
10. Greece   171 – 157 -8 1.29 1.72 
11. Canada 2011-13  266 – 155 -42 0.83 1.43 
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11. Switzerland 93   281 – 155 -45 0.79 1.39 
13. Belgium   297 – 154 -48 0.74 1.27 
14.USA   249 – 150 -40 0.89 1.48 
15. Australia      235 – 143 -42 0.86 1.50 
16. Portugal 2012-14   194 – 139 -28 1.01 1.79 
17. Sweden      198-   134 -32 0.95 1.69 
18. Finland          186 – 131 -30 0.99 1.76 
19. Spain    192 – 123 -36 0.90 1.61 
20. Norway      212 – 118 -46 0.78 1.39 
21. Japan        68 -   99 +46 1.90 3.91 
MDC Average (-UK)  236- 156 -34   
Correlating ranks of % reduction with %GDPEH Rho= -0.0872 n.sig.  
UK:MDC Significantly different CI in BOLD 
 
Table 3: Female Breast Cancer Deaths ASDR per million 1989-91 v 2013-15 ranked by highest rates. Confidence 
intervals Compares UK with Other Major Developed Countries. 
 
Country,  Years & Current rank Prostate 1989 v 2015 % Change 
CI UK: MDC 
Lower Upper 
1.Norway  280-   213 -24 0.74 1.28 
2.Sweden      267-   210 -21 0.77 1.32 
3.Denmark      249 -   207 -17 0.81 1.40 
4.New Zealand 2011-13 237-   168 -29 0.68 1.21 
5.UK         214 – 167 -22  0.75 1.33 
6.Ireland 2012-14 230 -  163 -29 0.68 1.21 
7.Netherlands 237 -  161 -32 0.65 1.16 
8.Switzerland 93 248-   156 -37 0.61 1.07 
9.Finland          236-    155 -34 0.63 1.12 
10.Portugal 2012-14 185 – 154 -17 0.79 1.43 
11.Australia 230 -   147 -36 0.61 1.09 
12.Germany 1990 212 -   145 -32 0.65 1.17 
13.Austria  231 -   130 -44 0.54 0.97 
14.Belgium   238 -   123 -49 0.49 0.89 
15.France 2012-14  223-    122 -45 0.52 0.95 
16. Canada 2011-13 217 -   120 -45 0.52 0.96 
17.Greece    108-    115 +6 0.98 1.90 
18.Spain  170 – 111 -35 0.61 1.14 
19.USA      218-   108 -50 0.47 0.86 
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20.Italy  149-    93 -38 0.58 1.11 
21.Japan  50 –    60 +20 1.00 2.36 
Average (- UK) % change 210-143 -32   
Correlating ranks of % reduction with %GDPEH Rho= +0.15378 p<0.01 
UK: MDC Significantly different  CI in BOLD 
 
Table 4: Prostate Cancer Deaths ASDR per million 1989-91 v 2013-15. Ranked by highest rates. Confidence 
intervals Compares UK with Other Major Developed Countries. 
 
Country & Years Breast Ratio of Change Prostate Ratio  of Change Chi Square P value 
1.UK                0.53 0.78 7.43 -  p<0.006 
2.Denmark      0.60 0.83 6.05 –  p<0.02 
3.Norway       0.54 0.76 4.56 – p<0.04 
4.France     0.72 0.55 5.30 -   p<0.03 
6=.Japan     1.46 1.20 2.19 -  p<0.2 
6=.New Zealand  0.60 0.71 1.63 -  p<0.2 
6=.USA       0.60 0.50 1.56 -  p<0.2 
9=Ireland   0.61 0.71 1.15 -  p<0.3 
9=.Sweden      0.68 0.79 1.07 -  p<0.3 
9=.Portugal   0.72 0.83 0.93 -  p<0.3 
12=.Greece     0.92 1.06 0.73 -   p<0.4 
12=.Switzerland  0.55 0.63 0.85 -  p<0.4 
12=.Austria     0.64 0.54 0.74 -   p<0.4 
15=.Netherlands 0.63 0.68 0.33 -  p<0.6 
15=.Italy        0.69 0.62 0.33 -  p<0.6 
17=.Germany  0.73 0.68 0.16 -   p<0.7 
17=.Finland           0.70 0.66 0.23 -   p<0.7 
19.Canada   0.58 0.55 0.12 -   p<0.8 
20=.Spain     0.64 0.65 0.13 -  p<0.9 
20=.Belgium   0.52 0.51 0.10 -   p<0.9 
Significant in BOLD 
 
Table 5: Chi Square Results Comparing Changes in Breast v Prostate Mortality 1989-2015. Ranked By Widest 
Breast v Prostate Reduction. 
 
4. Discussion 
4.1 Limitations   
This study is inevitably a broad-brush analysis. Whilst it  
demonstrates there have been differences between  
British female breast and prostate cancer outcomes, we 
do not know about any changes in cancer deaths in other 
male sites, which might have accounted for the 
comparatively good Total cancer outcomes for UK 
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males. Furthermore, this study cannot explain the 
reasons for the significant differences that have been 
identified between the UK and other countries which 
will require country-specific further research. 
Notwithstanding, the study provides a baseline to 
measure any future progress. The null hypothesis can be 
partly rejected as UK male and female Total cancer 
mortality rates fell proportionally more than four other 
major developed countries and none had improved more 
than Britain. However, whilst the UK did significantly 
better than five other MDC for breast cancer mortality 
the UK had a substantially worse outcome than five 
nations for prostate cancer over the period. Thus, 
relatively and comparatively, British males did less well 
than UK females. In relation to prostate and breast 
cancer France and Norway had relatively different 
outcomes for their exemplar male female cancer rates. 
We can only speculate as to why this might have 
happened. 
 
One salient finding is that every country has reduced its 
Total male and female cancer deaths which reflects well 
on cancer services in most countries and should be a 
boost for the morale of patients and front-line staff. It is 
noteworthy that reductions of UK Total male and 
female plus female breast cancer rates were better than 
the average falls of the other countries. This should 
provide a more positive message than studies of poorer 
UK survival rates [1-3]. However, despite these 
undoubted improvements, UK actual mortality rates are 
still slightly higher than the average of the other MDC 
total, breast and prostate cancers. Nevertheless, it should 
be remembered that the UK had the lowest average 
%GDPEH over the 1980-2016 period which is a 
nation’s fiscal context in which all services operate. 
Indeed it has been found that whilst currently the UK is 
13th highest of the twenty-one MDC in terms of current 
percentage of GDP on health, over the period from 1980 
to 2016, the UK still has the lowest average of all 
nations over the period [25, 26]. Whilst this reflects 
very positively on the total male and female reductions 
in cancer mortality, it highlights the relatively weaker 
outcome of the UK’s prostate results, which must be a 
matter of concern. The importance of an effective early 
diagnosis for both prostate and breast cancers is 
recognised and it has been argued that PSA screening is 
the most effective way forward [19, 20], although some 
have expressed concern about cost [21]. MRI 
approaches might be superior in determining the risk 
related to aggressive prostate cancer but cost and access 
are potential issues although the role of MRI in prostate 
cancer screening is to be the study of an upcoming trial 
(ReIMAGINE) [27]. 
 
However, there continues to be a problem of over-
diagnosis and some unnecessary invasive treatment [2]. 
For whilst prostate cancers are a major cause of 
European mortality, twenty years after testing it was 
found that around 100 men need to be screened to 
prevent one prostate cancer death although PSA testing 
has contributed to reduced prostate cancer mortality 
[29] as well as a strategy of active surveillance that 
reduces unnecessary invasive procedures [19, 20]. 
Against this background of an encouraging reduction in 
prostate cancer deaths, it is difficult to explain the 
relative anomaly of the UK results, especially against 
general improvements in overall UK male cancer 
outcomes, in comparison with British female breast 
cancer results over the period. The medical and 
technological developments related to urology and 
cancer treatments are recognised across the Western 
world, so might the UK’s worsened position be due to 
British urology services being proportionately less well 
funded than others, though a recent direct comparison 
on 24 mortality categories, the UK had significantly 
lower overall rates than the USA [30].   
 
One barrier to early PSA testing and screening is the  
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concern about possible stress to the patient surrounding 
such a potential diagnosis.  However, a British study 
found most men were quite resilient, though results 
were negatively influenced by socio-economic factors 
[31] but relatively easy access to a GP can help in 
avoiding these problems [15]. Indeed, apart from 
disproportionate high anxiety about colorectal cancer, 
anxieties surrounding screening for cancer are relatively 
quickly resolved [32]. This brings us to the conclusion 
that there is need for UK specific research to seek to 
explain this apparent anomaly so that urology services 
for prostate cancer, whilst undoubtedly improved, can 
match the successes seen with UK breast and total 
cancer services.  
 
One possible reason for the slower improvements in 
prostate cancer outcomes may be due to a lack of a 
sustained public campaign, as it does not seem that 
British men are more anxious about screening for 
prostate [30]. Such an approach should and could be 
positive, highlighting that prostate cancer mortality rates 
have never been lower and treatment more effective and 
that the PSA test is very simple although PSA screening 
is not endorsed by the British Association of Urological 
Surgeons. However, a new initiative by Prostate Cancer 
UK has called for a March for Men, similar to the 
Breast Cancer UK awareness project as it recognised 
the apparent reluctance of men to recognise problems 
and seek help for them. Crucially anything that would 
encourage men to come forward earlier to their GP’s 
`well-men’ project, may lead to British prostate 
mortality rates being even lower. However, overall, 
these results should be encouraging for patients, their 
families and front-line staff, especially in the UK, which 
continues to clinically achieve proportionally more with 
financially relatively less [30]. 
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